Price movement over the last 24 hours
Acadia Healthcare Company Inc vs ClearPoint Neuro Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.67 (market cap $2.94B), while ClearPoint Neuro Inc trades at $17.39 (market cap $524.82M). The key difference: Acadia Healthcare Company Inc is far larger — about 5.6× ClearPoint Neuro Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| ACHC | CLPT | |
|---|---|---|
Market Cap | $2.94B | $524.82M |
Sector | Health | Health |
52-Week High | $31.92 | $29.60 |
52-Week Low | $11.68 | $8.66 |
Enterprise Value | $5.45B | $552.81M |
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
ClearPoint Neuro (CLPT) trades at $18.00, down 3.85% with a bullish technical signal from moving averages. The company shows strong revenue growth with 25% organic device growth in Q1 2026 but continues to report significant losses, with a net income margin of -71.57%. Recent FDA clearance for the Velocity Alpha surgical drill and partnership expansion in South Korea highlight ongoing business development. Analyst sentiment remains strongly positive with 100% buy ratings, though the stock faces execution and regulatory risks.
The outlook remains speculative with high growth potential from gene therapy commercialization offset by persistent losses and cash burn. Investment opportunity lies in successful partner therapy commercialization, but risks include regulatory hurdles and the need for continued financing. The stock's valuation at 12.76x sales reflects growth expectations despite negative profitability metrics.
Trailing returns across standard periods
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →